Ethmoid sinus leiomyosarcoma after cyclophosphamide treatment.
Reich
D S
DS
Department of Surgery, University of Alabama at Birmingham, USA.
Palmer
C A
CA
Peters
G E
GE
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000601:surgery; D002273:Carcinogens / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy / Q000601:surgery; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects*; D005005:Ethmoid Sinus / Q000473:pathology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007890:Leiomyosarcoma / Q000139:chemically induced*; D015411:Mastectomy, Modified Radical; D008558:Melphalan / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D010255:Paranasal Sinus Neoplasms / Q000139:chemically induced*
D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D002273:Carcinogens; D003520:Cyclophosphamide; D008558:Melphalan; D005472:Fluorouracil; D008727:Methotrexate